Dr Paula Rodríguez-Otero speaks to ecancer at ASCO 2024 about the MRD analysis results from the PERSEUS trial.

This trial evaluated daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

She reports that daratumumab plus bortezomib/lenalidomide/dexamethasone followed by maintenance significantly increased the proportion of patients achieving minimal residence disease negativity.

Dr Rodríguez-Otero adds that there is a deepening of the response across the treatment, particularly during the maintenance phase.